Assessing Safety and Efficacy of Preoperative and Post-Transplant C1 Inhibitor (Berinert) vs. Placebo in Recipients of a Renal Allograft From Deceased High Risk Donors and Its Impact on DGF and IRI

Trial Profile

Assessing Safety and Efficacy of Preoperative and Post-Transplant C1 Inhibitor (Berinert) vs. Placebo in Recipients of a Renal Allograft From Deceased High Risk Donors and Its Impact on DGF and IRI

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs Complement C1 inhibitor protein (Primary)
  • Indications Delayed graft function; Reperfusion injury
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Apr 2018 Primary endpoint (Number of dialysis sessions per patient in the first 7 days post transplant.) has not been met as per the results published in the American Journal of Transplantation.
    • 10 Apr 2018 Results published in the American Journal of Transplantation
    • 18 Dec 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top